FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897514786> ?p ?o ?g. }

• W2897514786 abstract "Background: Filgotinib (FIL), an oral selective JAK1 inhibitor, has shown good safety and efficacy in two phase 2b studies (background methotrexate (MTX, DARWIN 1) and as monotherapy (DARWIN 2)) in active rheumatoid arthritis (RA) patients with inadequate response to MTX1,2. We conducted a large-scale RNA sequencing study of genes expressed in blood samples from these studies. Objectives: Identify RA-associated gene transcripts that are altered in response to FIL treatment. Methods: PAXgene blood samples from 242 RA patients receiving either a stable dose of MTX and placebo (PBO) or FIL 200 mg once daily (QD, DARWIN 1); or PBO, FIL 100 mg, or 200 mg monotherapy QD (DARWIN 2), were collected and analyzed at baseline, week 1 and/or week 12. RNA in whole blood was sequenced (Illumina HiSeq 2500) after globin depletion. Differential gene expression analysis was performed on all time-paired data after subtracting gene expression changes in the PBO group. Spearman’s rank correlation of gene expression to time, dose, and disease activity score (DAS28) were calculated on samples without missing values. A false-discovery rate (FDR) of 10% was applied for all analyses Results: Top-ranked gene sets positively associated with DAS28 disease activity at baseline over both studies included interferon alpha (IFN-α) and IFN gamma (IFN-γ) response, IL6/JAK/STAT3 signaling, and toll-like receptor signaling pathways (FDR 1CPM in at least 5% of the samples, 607 were differentially expressed following FIL treatment in either DARWIN1 or DARWIN2 with 48 genes significant in both studies (FDR Figure 1 Heatmap of 453 DAS28-correlated genes and the corresponding change in gene expression with 12 wk FIL in Phase2b RA studies Conclusions: RA patients treated with FIL show reproducible changes in gene expression consistent with modulation of JAK/STAT signaling and innate and adaptive immunity. FIL was shown to partially reverse the dysregulated gene expression profile associated with baseline DAS28 score, consistent with the efficacy observed in RA patients. References [1]Kavanaugh A, et al. Ann Rheum Dis2017;76:1009–19. [2]Westhovens R, et al. Ann Rheum Dis2017;76:998–1008. Disclosure of Interest: P. Taylor Consultant for: AbbVie, Biogen, BMS, Galapagos, GSK, Janssen, Lilly, MSD, Novartis, Sandoz, UCB;, J. Tarrant Employee of: GSI Employee, L. Zhao Employee of: GSI Employee, Y. Gindin Employee of: GSI Employee, A. Mirza Employee of: GSI Employee, P. Harrison Employee of: GLPG Employee, C. Tasset Employee of: GLPG Employee, R. Galien Employee of: GLPG Employee, A. Van der Aa Employee of: GLPG Employee, B. Downie Employee of: GSI Employee" @default.
• W2897514786 created "2018-10-26" @default.
• W2897514786 creator A5018680433 @default.
• W2897514786 creator A5023181600 @default.
• W2897514786 creator A5030901098 @default.
• W2897514786 creator A5039039186 @default.
• W2897514786 creator A5049261212 @default.
• W2897514786 creator A5059323796 @default.
• W2897514786 creator A5065013634 @default.
• W2897514786 creator A5068192104 @default.
• W2897514786 creator A5085019532 @default.
• W2897514786 creator A5086268219 @default.
• W2897514786 date "2018-06-01" @default.
• W2897514786 modified "2023-09-23" @default.
• W2897514786 title "SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis" @default.
• W2897514786 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3759" @default.
• W2897514786 hasPublicationYear "2018" @default.
• W2897514786 type Work @default.
• W2897514786 sameAs 2897514786 @default.
• W2897514786 citedByCount "0" @default.
• W2897514786 crossrefType "proceedings-article" @default.
• W2897514786 hasAuthorship W2897514786A5018680433 @default.
• W2897514786 hasAuthorship W2897514786A5023181600 @default.
• W2897514786 hasAuthorship W2897514786A5030901098 @default.
• W2897514786 hasAuthorship W2897514786A5039039186 @default.
• W2897514786 hasAuthorship W2897514786A5049261212 @default.
• W2897514786 hasAuthorship W2897514786A5059323796 @default.
• W2897514786 hasAuthorship W2897514786A5065013634 @default.
• W2897514786 hasAuthorship W2897514786A5068192104 @default.
• W2897514786 hasAuthorship W2897514786A5085019532 @default.
• W2897514786 hasAuthorship W2897514786A5086268219 @default.
• W2897514786 hasBestOaLocation W28975147861 @default.
• W2897514786 hasConcept C104317684 @default.
• W2897514786 hasConcept C126322002 @default.
• W2897514786 hasConcept C142724271 @default.
• W2897514786 hasConcept C143998085 @default.
• W2897514786 hasConcept C150194340 @default.
• W2897514786 hasConcept C203014093 @default.
• W2897514786 hasConcept C204787440 @default.
• W2897514786 hasConcept C27081682 @default.
• W2897514786 hasConcept C2777575956 @default.
• W2897514786 hasConcept C2781059491 @default.
• W2897514786 hasConcept C54355233 @default.
• W2897514786 hasConcept C71924100 @default.
• W2897514786 hasConcept C86803240 @default.
• W2897514786 hasConcept C90924648 @default.
• W2897514786 hasConceptScore W2897514786C104317684 @default.
• W2897514786 hasConceptScore W2897514786C126322002 @default.
• W2897514786 hasConceptScore W2897514786C142724271 @default.
• W2897514786 hasConceptScore W2897514786C143998085 @default.
• W2897514786 hasConceptScore W2897514786C150194340 @default.
• W2897514786 hasConceptScore W2897514786C203014093 @default.
• W2897514786 hasConceptScore W2897514786C204787440 @default.
• W2897514786 hasConceptScore W2897514786C27081682 @default.
• W2897514786 hasConceptScore W2897514786C2777575956 @default.
• W2897514786 hasConceptScore W2897514786C2781059491 @default.
• W2897514786 hasConceptScore W2897514786C54355233 @default.
• W2897514786 hasConceptScore W2897514786C71924100 @default.
• W2897514786 hasConceptScore W2897514786C86803240 @default.
• W2897514786 hasConceptScore W2897514786C90924648 @default.
• W2897514786 hasLocation W28975147861 @default.
• W2897514786 hasOpenAccess W2897514786 @default.
• W2897514786 hasPrimaryLocation W28975147861 @default.
• W2897514786 hasRelatedWork W1981416033 @default.
• W2897514786 hasRelatedWork W2287189912 @default.
• W2897514786 hasRelatedWork W2312718542 @default.
• W2897514786 hasRelatedWork W2312968583 @default.
• W2897514786 hasRelatedWork W2532183409 @default.
• W2897514786 hasRelatedWork W2571716321 @default.
• W2897514786 hasRelatedWork W2573945840 @default.
• W2897514786 hasRelatedWork W2593992051 @default.
• W2897514786 hasRelatedWork W2755476950 @default.
• W2897514786 hasRelatedWork W2915673740 @default.
• W2897514786 hasRelatedWork W2951978591 @default.
• W2897514786 hasRelatedWork W2953306569 @default.
• W2897514786 hasRelatedWork W2953598534 @default.
• W2897514786 hasRelatedWork W2988304265 @default.
• W2897514786 hasRelatedWork W3011854830 @default.
• W2897514786 hasRelatedWork W3030775188 @default.
• W2897514786 hasRelatedWork W3035347814 @default.
• W2897514786 hasRelatedWork W3105988118 @default.
• W2897514786 hasRelatedWork W3111170703 @default.
• W2897514786 hasRelatedWork W3164340015 @default.
• W2897514786 isParatext "false" @default.
• W2897514786 isRetracted "false" @default.
• W2897514786 magId "2897514786" @default.
• W2897514786 workType "article" @default.